Recognition of target antigens with normal, post-BMT, and post-DLI serum
Gene products . | Healthy donors, n = 20 . | Acute GVHD, n = 5 . | Chronic GVHD, n = 20 . | TCD BMT, n = 10 . | Myeloma DLI responders, n = 9 . | Myeloma DLI nonresponders, n = 5 . | CML DLI responders, n = 5 . |
|---|---|---|---|---|---|---|---|
| Dihydrolipoamide acetyltransferase | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| KIAA0053 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| BCMA | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| FLJ10330 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| ROCK-1 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| Similar to hepatoma-derived growth factor | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Homer-3 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Bif-1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Heterogeneous nuclear ribonucleoprotein D—like | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| SON DNA | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| FLJ10534 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| SFRS | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| AT-rich sequence-binding protein | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
Gene products . | Healthy donors, n = 20 . | Acute GVHD, n = 5 . | Chronic GVHD, n = 20 . | TCD BMT, n = 10 . | Myeloma DLI responders, n = 9 . | Myeloma DLI nonresponders, n = 5 . | CML DLI responders, n = 5 . |
|---|---|---|---|---|---|---|---|
| Dihydrolipoamide acetyltransferase | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| KIAA0053 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| BCMA | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| FLJ10330 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| ROCK-1 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| Similar to hepatoma-derived growth factor | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Homer-3 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Bif-1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Heterogeneous nuclear ribonucleoprotein D—like | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| SON DNA | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| FLJ10534 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| SFRS | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| AT-rich sequence-binding protein | 1 | 0 | 1 | 0 | 1 | 0 | 0 |